The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
University of Cincinnati researchers have found that certain treatments for cancer may increase the chance of death if they contract COVID-19.
Researchers at the University of Bern have discovered a mechanism in the body's own immune system which is responsible for the maturation and activation of immune cells. In the fight against skin cancer, the results have the potential to help immunotherapies succeed, even in patients for whom they have so far been ineffective.
Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell's life span offers a potential second route to defeat the disease--and solid tumorous cancers as well.
Researh teams of Tokyo Medical and Dental University (TMDU) and Harvard Medical School (HMS) have uncovered how to increase the efficacy of anti-PD-L1 immunotherapy. Using a combination of molecular, biochemical, and bioinformatics approaches, they discovered that the nuclear localization of PD-L1 is controlled by acetylation at a single, specific, Lys site. In the nucleus, PD-L1 controls the expression of immune related genes. Therefore, targeting PD-L1 nuclear localization could enhance the efficacy of PD-1/PD-L1 blockade based immunotherapies.
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
A single-center observational study of more than 1,000 oncological examinations has demonstrated that positron emission tomography/magnetic resonance imaging (PET/MRI) facilitates cancer staging as well as PET/computed tomography (PET/CT) and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step.
Limitations in DNA sequencing technology make it difficult to detect some major mutations often linked to cancer, such as the loss or duplication of parts of chromosomes. Now, methods developed by Princeton computer scientists will allow researchers to more accurately identify these mutations in cancerous tissue, yielding a clearer picture of the evolution and spread of tumors than was previously possible.
Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries, according to results from studies presented at ESMO 2020.
A dangerous protein named SNAI2 helps cancers metastasize and shields cancer from both the immune system and chemotherapy. Worse, SNAI2 is in a family of proteins that are notoriously hard to fight with drugs. But now Princeton University's Yibin Kang and his colleagues have found a way to use the cell's recycling system to control SNAI2, providing a new possibility for treatments.